Fecal α1arantitrypsin clearance in patients with inflammatory bowel disease

Bruce B. Grill, A. Craig Hillemeier, Woyce D. Gryboski

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


We evaluated fecal clearance of α1-antitrypsin (α1AT) as a method of detecting and quantitating intestinal protein loss in patients with inflammatory bowel disease. We investigated α1AT clearance (Cα1-AT) in 14 patients (seven with Crohn’s disease, seven with ulcerative colitis) and in 10 children with gastrointestinal disorders and normal serum albumin values who served as controls. The inflammatory bowel disease patients were analyzed for nutritional status, intestinal absorption, disease activity and distribution, and presence or absence of rectal bleeding. α1AT was measured in stool (72-h collections) and serum by radial immunodiffusion, and the clearance was calculated. The mean Cα1-ATin patients with inflammatory bowel disease was significantly (p < 0.05) higher than that of the controls. Cα1-ATin the former patients was inversely related to the serum albumin level (p < 0.001), but not to disease activity, medications, absorption, nutritional status, or moderate rectal bleeding. In the patients with Crohn’s disease there was a trend to increased Cα1-ATfrom only ileal to diffuse small intestinal disease involvement. We conclude that in patients with inflam-matory bowel disease, fecal clearance of α1-AT is a useful method for quantitating intestinal protein loss, and that moderate rectal bleeding does not affect the Cα1-ATdetermination.

Original languageEnglish (US)
Pages (from-to)56-61
Number of pages6
JournalJournal of pediatric gastroenterology and nutrition
Issue number1
StatePublished - Jan 1984

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology


Dive into the research topics of 'Fecal α1arantitrypsin clearance in patients with inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this